BioLuminate Breast Cancer Detector R&D Delayed By Financing Drought
This article was originally published in The Gray Sheet
BioLuminate will launch a 12-center, 1,000-patient Phase III pivotal trial to support a PMA application for its Smart Probe breast cancer detection tool as an adjunct to mammography, following completion of a 150-patient Phase I/II study later this year
You may also be interested in...
Proposals allowing FDA's approval criteria to play a greater role in Medicare coverage determinations should account for the fact that many devices are cleared via 510(k) and not reviewed for clinical effectiveness, CDRH Director David Feigal asserted Oct. 11
FDA and CMS should issue a memorandum of understanding on maintaining confidentiality and trade secrets during collaborations between the agencies in evaluating new devices, according to the HHS Secretary's Advisory Committee on Regulatory Reform
San Jose-based BioLuminate expects to be profitable in 2003, immediately following the commercial release of its Smart Probe breast cancer detection diagnostic tool. The privately held start-up began operations in April 2000.